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Combination of the CCL5-Derived Peptide R4.0 with Different HIV-1
Blockers Reveals Wide Target Compatibility and Synergic Cobinding
to CCR5
Massimiliano Secchi,a Lia Vassena,a* Sébastien Morin,b* Dominique Schols,c Luca Vangelistaa
Division of Immunology, Transplantation, and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italya; Division of Structural Biology, Biozentrum, University of
Basel, Basel, Switzerlandb; Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgiumc
R4.0, a synthetic CCL5/RANTES-derived peptide, exerts potent anti-HIV-1 activity via its nonactivating interaction with CCR5,
the major HIV-1 coreceptor. CCR5 chronic activationmay promote undesirable inflammatory effects and enhance viral infec-
tion; thus, receptor antagonism is a necessary requisite. HIV-1 gp120, CCL5, andmaraviroc dock on CCR5 by sharing two recep-
tor sites: the N terminus and the second extracellular loop. In combination studies, R4.0, CCL5, andmaraviroc exhibited con-
comitant interactions with CCR5 and promoted synergic inhibition of HIV-1 in acute-infection assays. Furthermore, various
degrees of additive/synergic HIV-1 inhibition were observed when R4.0 was tested in combination with drugs and lead com-
pounds directed toward different viral targets (gp120, gp41, reverse transcriptase, and protease). In combination with tenofovir,
R4.0 provides cross-clade synergic inhibition of primary HIV-1 isolates. Remarkably, an in vitro-generated maraviroc-resistant
R5 HIV-1 strain was inhibited by R4.0 comparably to the wild-type strain, suggesting the presence of viral resistance barriers
similar to those reported for CCL5. Overall, R4.0 appears to be a promising lead peptide with potential for combination in anti-
HIV-1 therapy and in microbicide development to prevent sexual HIV-1 transmission.
More than 34 million people worldwide are presently livingwith human immunodeficiency virus type 1 (HIV-1) (1),
the causative agent of the AIDS, a pandemic that has killed more
than 25 million people in 3 decades. Despite the highly active
antiretroviral therapy (HAART), three major burdens remain for
HIV-1 infection. The HAART has prohibitive costs for the vast
majority of HIV-1-infected people, there is no therapeutic route
that allows the eradication of the virus after infection (2), and
there are no preventive measures that may warrant safety to a
significant percentage of the population at risk of infection. Effi-
cacious preventive measures are of the utmost importance and,
while a protective HIV-1 vaccine is still a remote perspective, al-
though positive hints are emerging (3, 4), topical anti-HIV-1 mi-
crobicides represent a promising alternative, as well as an option
complementary to a vaccine (5). Microbicides embrace several
formulations and molecular targets, and the concept of combin-
ing two or more lead compounds to decrease the insurgence of
drug resistance and to increase prevention efficacy is progressively
becoming a common trend (6). The HIV-1 coreceptor CCR5,
exclusively used in primary infection, represents an important
microbicide target since it is present on the surfaces of CD4 T
lymphocytes and macrophages localized in the vaginal, rectal, and
foreskin epithelia (7). Any HIV-1 inhibitor targeting CCR5, pref-
erably an antagonist, may therefore be seen as a potential micro-
bicide. Maraviroc (MVC) and certain full-length and short pep-
tide derivatives of CCL5/RANTES may well suit the requirements
for the development of an effective HIV-1 microbicide (8–10).
CCR5 antagonism (receptor binding devoid of activating capac-
ity) is a fundamental requisite to prevent mucosal inflammation,
as inflammation may very likely result in the enhancement of
HIV-1 transmission.
Extensive efforts are being pursued to engineer CCL5 deriva-
tives with high anti-HIV-1 potency to act as entry inhibitors and
CCR5 antagonists (11). In this context, a long-lasting project has
been focused on the design of potent peptide-based HIV-1 entry
inhibitors (12–14), with R4.0 as the most active representative
(10). In view of its possible implementation in combination pro-
tocols, R4.0 was tested in various cellular assays for its compati-
bility with several HIV-1 inhibitors directed toward different vi-
ral/cellular targets. R4.0 was revealed to be fully suitable for
combinations with all compounds tested, including CCR5-di-
rected inhibitors, proving itself a valuable new compound in anti-
HIV-1 therapy and microbicide development.
MATERIALS AND METHODS
Peptide synthesis. Peptides R3.0 and R4.0 were synthesized by standard
solid-phase protocols using Fmoc chemistry and purified by reverse-
phase high-performance liquid chromatography (RP-HPLC) to 95%
purity, as described previously (10). Peptides were dimerized by oxidation
of the N-terminal cysteine residues and N-terminally acetylated. For sta-
ble dimerization, peptides were incubated overnight in 50% dimethyl
sulfoxide (DMSO) (Sigma, St. Louis, MO) in water; DMSO was removed
by freeze-drying, and the dimerized peptides were purified by RP-HPLC.
The purity of the final stock was97%; the Ellman test for free sulfhydryl
groups was negative.
Drug supply and formulation. MVC (Pfizer, New York, NY) and
tenofovir disoproxil fumarate (TDF) (Gilead, Foster City, CA) tablets
(150 mg and 300 mg, respectively) were used for in vitro assays. Both
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tablets were ground into a powder and dissolved in a known volume of
sterile water. Then, the preparations were filtered to remove a small
amount of insoluble material (tablet excipients) and stored in aliquots at
20°C. Two hundred milligrams of emtricitabine (FTC) powder con-
tained in a capsule (Gilead) was dissolved in sterile water, filtered, and
stored in aliquots at20°C.
HIV-1 Env-mediated cell fusion assay. Antiviral activity was evalu-
ated using two cellular assays, an HIV-1 envelope-mediated cell fusion
assay and an acute HIV-1 infection assay (10), both based on the proto-
type CCR5-using (R5) isolate HIV-1BaL. The cell fusion assay was per-
formed using a modification of the test based on vaccinia virus technol-
ogy, originally developed by Nussbaum and coworkers (15). In the
modified assay, the effector cells were chronically infected PM1 cells,
whereas the target cells were NIH 3T3 mouse fibroblasts or HeLa TZM-bl
cells stably expressing human CCR5 and human CD4. Sixteen hours be-
fore the test, effector cells were infected with a vaccinia virus vector ex-
pressing bacteriophage T7 RNA polymerase, while target cells were in-
fected with a vaccinia virus vector expressing the lacZ reporter gene under
the control of the T7 promoter. All vaccinia virus infections were per-
formed in Dulbecco’s modified Eagle’s medium (DMEM) (Lonza Bio-
Whittaker, Valais, Switzerland) supplemented with 2.5% fetal bovine se-
rum (FBS) (Lonza BioWhittaker). The cells were then washed with 2.5%
DMEM, and the effector cells were mixed for 2 h with the target cells in the
presence or absence of the inhibitors. Cell fusion was determined by mea-
surement of -galactosidase activity in nonionic detergent cell lysates as
described previously (15).
In addition, another modified fusion assay was used, as previously
reported (10). In this assay, primary CD4 T lymphocytes purified from
human peripheral blood mononuclear cells (PBMC) were used as target
cells instead of NIH 3T3 or TZM-bl cells. Briefly, PBMC were isolated by
Lympholyte cell separation medium (Cedarlane Laboratories Limited,
Burlington, Canada) gradient centrifugation of buffy coat preparations
from healthy blood donors. Afterwards, PBMC were stimulated with 500
U/ml recombinant human interleukin 2 (IL-2) (Chiron, Emeryville, CA)
in complete RPMI medium (Lonza BioWhittaker) for 7 to 21 days to
induce surface expression of CCR5. The day before the fusion assay,
CD4T cells were purified from PBMC by negative selection using Dyna-
beads goat anti-mouse IgG (Invitrogen, Carlsbad, CA) and a cocktail of
purified monoclonal antibodies (MAbs) against human CD19, CD16,
CD56, CD8 (Immunotools, Friesoythe, Germany), and CD14 (AbD Se-
rotec, Raleigh, NC). CD4 T cells were then infected with the vaccinia
virus vector expressing the lacZ reporter gene under the control of the T7
promoter. Infection was carried out in DMEM in the absence of FBS
during the first 2 h, and then the cells were diluted using DMEM supple-
mented with 2.5% FBS. The following day, CD4 T cells (target) were
incubated with effector cells (PM1 cells chronically infected with HIV-1BaL)
for 4 h in the absence or presence of inhibitors. After incubation, cells were
lysed and cell fusion was determined as described above.
HIV-1 infection assay.Acute HIV-1 infection was obtained by adding
HIV-1BaL and the primary isolates 5513 and 98IN007 (50 50% tissue cul-
ture infective doses [TCID50]/well) to PM1 cells (2  10
4/well) in com-
plete RPMI medium. PM1 is a unique CD4 CCR5 T cell clone suscep-
tible to a wide variety of primary HIV isolates, including those exclusively
using CCR5 as the coreceptor (16). Instead, acute-infection HIV-1 RU570
(Russian G isolate) and RU570 MVC-resistant strains were obtained by
adding the viral stocks (50 TCDI50/well) to 1  10
5 cells/well of PBMC
isolated from buffy coat cells as described above and activated for 4 days
with 5 g/ml of phytohemagglutinin (PHA). Experiments were per-
formed in triplicate using 96-well round-bottom microtiter plates in
the presence or absence of inhibitors. After incubation at 37°C for 16 h,
the wells were washed twice, and complete medium, with or without the
inhibitors, was added. After 48 h, 75% of the supernatant was removed for
HIV-1 p24 antigen measurement and replaced by an equal volume of
medium containing the inhibitors. Virus replication was assayed at day 4
postinfection by the p24 antigen enzyme-linked immunosorbent assay
(ELISA). Supernatants were diluted in 1% Empigen BB detergent (Calbi-
ochem, Gibbstown, NJ) to disrupt virions, added to a 96-well ELISA plate
coated with anti-HIV-1 p24 polyclonal antibodies (Aalto Bio Reagents
Ltd., Dublin, Ireland), and incubated for 2 h at room temperature. The
plate was then washed three times in TBS buffer (1.5 M NaCl, 250 mM
Tris, pH 7.5), and an alkaline phosphatase-conjugated anti-HIV-1 p24
monoclonal antibody (Aalto Bio Reagents Ltd.) was added for 1 h at room
temperature. After the plates were washed three times with Tropix buffer
(10 mM MgCl2, 200 mM Tris, pH 9.8), p24 was detected by adding the
luminescence substrate CSPD Tropix (Applied Biosystems, Foster City,
CA) and the signal was analyzed using a Mithras LB 940 luminometer
(Berthold Technologies, Bad Wildbad, Germany). Levels of p24 were cal-
culated by generating a standard curve with HIV-1 p24 antigen standards.
Combinations and statistical analysis. Experimental design and
analysis of synergy, additivity, or antagonism between different com-
pounds were based on the combination index (CI) method of Chou and
Talalay (17, 18). In an HIV-1 cell fusion assay and an HIV-1 infection
assay, each drug was tested individually and in a fixed molar ratio (50%
infective concentration [IC50] to IC50) combination over a range of 2-fold
serial dilutions. The 50%, 75%, and 90% combination indexes (CI50, CI75,
and CI90) to determine the effect of the interactions between the drugs
were calculated using CalcuSyn software 2.0 (Biosoft, Ferguson, MO). A
CI of0.9 indicates synergy, a CI from 0.9 to 1.1 indicates additivity, and
a CI of1.1 indicates antagonism. Dose-response curves were fitted using
GraphPad Prism version 5.04 (GraphPad Software, San Diego, CA) in
order to calculate IC50s through nonlinear-regression analysis. All data
are expressed as the means	 standard deviations (SD) of results from two
independent experiments performed in triplicate. All P values were com-
puted according to the Fischer rule.
Immunofluorescence microscopy and cytofluorimetric analysis.
For immunofluorescence microscopy, 1  105 CHO CD4 CCR5 cells
were grown in 12-well plates on 18-mm glass coverslips (Zeus super) in
complete DMEM. One day later, cells were washed twice in phosphate-
buffered saline (PBS) and incubated at 37°C for 4 h in DMEM without
FBS in the presence of 100 nM CCL5, 100 nM R4.0, and 100 nM MVC.
Cells were washed twice in cold PBS, fixed with 3% fresh paraformalde-
hyde (Sigma) for 20 min, washed in PBS, and incubated with 50 mM
ammonium chloride (Sigma) for 30 min at room temperature to quench
free aldehydes. Then, fixed cells were incubated for 15 min at room tem-
FIG 1 Schematic representation of HIV-1 infection of CD4 T cells and the
inhibitors used in this study. A survey of R4.0 combinations (double or triple)
with different entry (CV-N, 2G12, MVC, and CCL5), fusion (T20, 2F5, and
4E10), and replication (FTC, TDF, and IDV) inhibitors yielded either full
additivity or synergy. Arrows indicate viral and cellular inhibitor targets. R4.0
(not illustrated) targets CCR5.
Secchi et al.
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perature in PBS containing 5% bovine serum albumin (BSA) (Sigma) to
saturate nonspecific binding sites, incubated for 20 min at 37°C with 5
g/ml 3A9 anti-CCR5 antibody (BD Bioscience, San Jose, CA), washed
three times with PBS containing 5% BSA, incubated for 20 min at 37°C
with 2g/ml donkey anti-mouse IgG (HL) Alexa Fluor 488 (Invitrogen,
Carlsbad, CA), and washed again. Finally, the coverslips were mounted
over Mowiol 4-88 (Sigma) and examined using a Zeiss Axiophot epifluo-
rescence microscope (Carl Zeiss Microscopy LLC, Thornwood, NY) un-
der a 63/1.40 oil immersion objective equipped with a Hamamatsu dig-
ital charge-coupled device (CCD) camera (model C4742-95; Hamamatsu
Photonics, Shizuoka, Japan).
Cytofluorimetric analysis for surface CCR5 expression was conducted
on 1  105 CHO CD4 CCR5 cells incubated for 4 h at 37°C in DMEM
without FBS in the presence of 100 nM CCL5, 100 nM R4.0, and 100 nM
MVC. After the treatment, cells were washed twice with cold PBS contain-
ing 2% FBS and fixed with 2% fresh formaldehyde (Sigma) for 15 min.
Then, the cells were incubated with the same primary and secondary an-
tibodies used in immunofluorescence for 15 min at 4°C. After being
washed, cells were analyzed using the Gallios flow cytometer (Beckman
Coulter Inc., Brea, CA) and data were analyzed using the FlowJo software
(Tree Star Inc., Ashland, OR).
RESULTS
R4.0 presents wide anti-HIV-1 compatibility with different in-
hibitors. The need for antiviral cocktails in HIV-1 infection ther-
apy and prevention is dictated by the escape routes of the virus.
Hence, it is mandatory to test new HIV-1 inhibitors for their ad-
FIG 2 Anti-HIV-1BaL activity of the CCL5-derived peptide R4.0 in combination with different HIV-1 entry and fusion inhibitors. (A to F) R4.0-induced HIV-1
inhibition tested by Env-mediated cell fusion inhibition assays in combination with CV-N (A), 2G12 (B), T20 (C), 2F5 (D), 4E10 (E), and MVC (F). (G) HIV-1
inhibition induced by the CCL5-derived peptide R3.0 (10) tested in combination with MVC by cell fusion inhibition assays using purified human CD4 T cells.
(H to I) R4.0-induced HIV-1 inhibition tested by cell fusion inhibition assays using purified human CD4 T cells in combination with T20 (H) or MVC (I). The
resulting dose-response curves of mixed inhibitors are referred to as R4.0 or R3.0 and indicated as “mix” (P values 0.0001). Values are the means	 SD of results
from two independent experiments performed in triplicate.
R4.0’s Wide Compatibility with Anti-HIV-1 Targets
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ditivity/synergy with existing drugs or other lead compounds. In
this regard, the CCL5-derived peptide R4.0, the most active lead
compound resulting from a long-lasting molecular evolution (10,
12–14), was subjected to an extensive combination survey. All
compounds tested with their viral and cellular targets are illus-
trated in Fig. 1. An initial assessment of R4.0’s additive, or even
synergic, anti-HIV-1 features was carried out in cell fusion inhi-
bition assays testing combinations with an array of different
HIV-1 blockers. The anti-HIV-1 agents tested were cyanovirin-N
(CV-N) and the MAb 2G12, recognizing the carbohydrate shield
of gp120 (19, 20); T20 and the MAbs 2F5 and 4E10, recognizing
gp41 (21–23); and MVC, a CCR5 antagonist (8) (Fig. 2). Combi-
nations of R4.0 with T20 and, separately, MVC were also tested in
cell fusion assays in which purified human CD4T cells were used
as target cells, as previously reported (10). Although R4.0 blocked
HIV-1 with low nanomolar potency, its IC50 improved when it
was used in combination with all the different compounds, as
illustrated with the dose-response curves of mixed inhibitors (Fig.
2). The calculated combination indexes (Table 1) indicated a syn-
ergic effect for the anti-HIV-1 MAbs and T20, with CI50s ranging
from 0.43 to 0.81, and an additive effect for CV-N and MVC, with
CI50s from 0.94 to 1.05. The strongest synergic interaction within
this panel of inhibitors was observed between R4.0 and 4E10, with
a CI50 value of 0.43, and the highest improvement in R4.0 antiviral
potency was obtained using 2F5 and 4E10, with a 5-fold and a
striking 18-fold IC50 increase, respectively.
The possibility of combining R4.0 with CV-N and MVC was
also examined in a more physiological assay in which PM1 cells
were infected with HIV-1BaL (Fig. 3A and B). The results of these
experiments are shown in Table 1 and revealed a reproducible
additive effect for R4.0 and CV-N and a synergic effect for R4.0
and MCV, with CI50s of 0.92 and 0.75, respectively. In this assay,
the R4.0 –CV-N combination confirms the value obtained in the
cell fusion assay, while the R4.0-MVC combination produces a
stronger effect.
The spectrum of different inhibitors tested in combination
with R4.0 was further expanded in acute-infection assays testing
the inhibition combination outside the entry/fusion landscape by
investigating intracellular HIV-1 inhibition. Hence, indinavir
(IDV), a protease inhibitor (24), and FTC and TDF, two reverse
transcriptase inhibitors (25, 26), were tested (Fig. 3C, D, and E).
IDV, FTC, and TDF inhibited HIV-1BaL replication with IC50s of
14.8 nM, 42 nM, and 10.2 nM, respectively. All the compounds
synergized with R4.0, yielding CI50 values ranging from 0.63 to
0.87, as reported in Table 1.
In a further effort to make a prospective microbicide cocktail,
a triple R4.0-IDV-TDF combination was used to inhibit acute
HIV-1BaL infection/replication in PM1 cells (Fig. 3F). Encourag-
ingly, the resulting inhibition corresponded to a synergic effect,
with a CI50 value of 0.83, improving R4.0’s antiviral potency about
3-fold.
Cobinding to CCR5 allows effective and expanded anti-
HIV-1 combinations at the receptor sites. The efficient simulta-
neous targeting of CCR5 using R4.0 and MVC (Fig. 2F and I and
3B) provides the basis to investigate this concept further and ex-
pands CCR5 targeting possibilities (Fig. 4). CCR5 binding and the
proficient anti-HIV-1 combination of CCL5 and MVC have al-
ready been reported (27). The latter finding was confirmed in our
experimental setup by testing the CCL5-MVC combination in
acute-infection assays, in which we observed an additive effect,
with a CI50 of 0.91, and in the human lymphocyte fusion assay, in
which we observed a synergic effect, with a CI50 of 0.66 (Fig. 4A
and B). Despite the likelihood for antagonism, a combination of
R4.0 and CCL5 was attempted in acute-infection assays (Fig. 4C).
Surprisingly, this combination yielded an additive effect, with a
CI50 of 0.9. Even more surprising was the successful attempt to
combine three CCR5 inhibitors, R4.0, MVC, and CCL5. The re-
sulting synergy presents a CI50 value of 0.58, improving R4.0’s
antiviral potency 11-fold.
R4.0’s antagonism toward CCR5 was previously assessed in a
TABLE 1 CI values for R4.0 or CCL5 in combination with other inhibitors
Drug(s) used in combination Experimental condition CI50 CI75 CI90 CI50 effect
Drugs used with R4.0
CV-N Fusion 0.94	 0.12 0.90	 0.08 0.88	 0.27 Additive
MVC Fusion 1.05	 0.03 1.00	 0.06 0.95	 0.08 Additive
T20 Fusion 0.78	 0.08 0.79	 0.01 0.80	 0.06 Synergy
2G12 Fusion 0.78	 0.19 0.66	 0.01 0.61	 0.14 Synergy
4E10 Fusion 0.43	 0.09 0.51	 0.19 0.79	 0.04 Synergy
2F5 Fusion 0.81	 0.20 0.82	 0.10 1.01	 0.09 Synergy
MVC Fusion T cells 1.05	 0.03 0.83	 0.06 0.66	 0.08 Additive
T20 Fusion T cells 1.08	 0.10 0.99	 0.03 0.94	 0.06 Additive
CCL5 p24 0.90	 0.04 0.88	 0.13 0.86	 0.21 Additive
CV-N p24 0.92	 0.15 0.96	 0.11 1.01	 0.07 Additive
MVC p24 0.75	 0.19 0.81	 0.13 0.87	 0.05 Synergy
FTC p24 0.87	 0.03 0.78	 0.03 0.71	 0.08 Synergy
TDF p24 0.67	 0.01 0.73	 0.01 0.78	 0.01 Synergy
IDV p24 0.63	 0.08 0.67	 0.07 0.72	 0.06 Synergy
TDF-IDV p24 0.83	 0.23 0.82	 0.08 0.86	 0.09 Synergy
TDF (5513) p24 0.49	 0.03 0.54	 0.02 0.58	 0.01 Synergy
TDF (98IN007) p24 0.77	 0.04 0.80	 0.04 0.84	 0.03 Synergy
MVC-CCL5 p24 0.58	 0.16 0.65	 0.14 0.77	 0.18 Synergy
Drugs used with CCL5
MVC Fusion T cells 0.66	 0.01 0.66	 0.04 0.69	 0.08 Synergy
MVC p24 0.91	 0.02 0.82	 0.01 0.78	 0.02 Additive
Secchi et al.
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chemotaxis assay in which the peptide exerted an activity similar
to that of MVC (10). This aspect was further verified here using
CHO CD4 CCR5 cells. As expected, the surface expression level of
CCR5 (stained using MAb 3A9) is reduced in CHO CD4 CCR5
cells treated with CCL5, while it is not affected when the cells are
treated with MVC or R4.0 (Fig. 5A to D). The level of cell surface
CCR5 was quantified also by flow cytometry, which showed a 40%
CCR5 internalization with CCL5, as previously reported (28), and
comparable antagonistic activity for MVC and R4.0 with no inter-
nalization of the receptor (Fig. 5E).
Validation of the R4.0-TDF combination on primary R5
HIV-1 strains. In order to further test the possible implementa-
tion of R4.0 as a candidate for a microbicidal combination, two
primary R5 HIV-1 isolates were tested, one belonging to clade B
(5513) and one belonging to clade C (98IN007). In acute-infec-
tion assays, R4.0 inhibited HIV-15513 and HIV-198IN007, with IC50s
of 56 nM and 196 nM, respectively. Both viruses are strongly in-
hibited by TDF (IC50s of 12.7 nM for HIV-15513 and 15.6 nM for
HIV-198IN007). The combination with TDF increased the antiviral
potency of R4.0 against the two primary viruses, showing a syner-
gistic profile comparable to that of the R4.0-TDF combination
observed for HIV-1BaL (Fig. 6A and B). The strongest synergy was
obtained with HIV-15513 (CI50 of 0.49), while a CI50 of 0.77 was
observed for HIV-198IN007. This result is particularly encouraging,
since primary clade C and B strains represent a significant portion
of HIV-1 R5 strains. In addition, TDF is widely used in microbi-
cide development and clinical trials, it is a drug component of
HAART, and, associated with FTC, it belongs to a recently ap-
proved oral preventive therapy (29).
CCL5 and R4.0 entry inhibition of an MVC-resistant R5
HIV-1 strain strengthens the concepts of differential CCR5
binding site usage and of R4.0 being a barrier to virus drug re-
sistance. Indirect evidence of the additive/synergic effect between
R4.0 or CCL5 and MVC was obtained using an MVC-resistant
strain, RU570 (MVC-RU570). MVC-RU570 is an in vitro-gener-
ated variant of the Russian clade G primary isolate RU570, which
FIG 3 Anti-HIV-1BaL activity of R4.0 in combination with HIV-1 inhibitors of different classes. (A to F) HIV-1 inhibition tested by acute-infection assays on the
human CD4 T cell clone PM1 and measured by a p24-based assay after 4 days of infection. R4.0 was tested in single combinations with CV-N (A), MVC (B),
IDV (C), FTC (D), and TDF (E) and in a triple combination with TDF and IDV (F). The dose-response curves of mixed inhibitors (mix) are referred to as R4.0
(P values 0.0001). Values are the means	 SD from two independent experiments performed in triplicate.
R4.0’s Wide Compatibility with Anti-HIV-1 Targets
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became completely resistant to MVC after long-term cell culture
of RU570 in the presence of MVC (30). The deletion of 3 amino
acids within the V3 loop of RU570 appears to be responsible for
the acquired resistance to MVC in that it provided the virus with
the ability to utilize MVC-bound CCR5 for its entry process (30).
PBMC from healthy donors were infected with the RU570 and
MVC-RU570 strains to determine viral infections in the presence
of MVC, CCL5, and R4.0. As illustrated in Table 2, MVC showed
no antiviral activity against MVC-RU570, while CCL5 and R4.0
inhibited the virus, with IC50s of 3.1 and 495 nM, respectively. The
superior anti-HIV-1 activity of CCL5 and R4.0 against MVC-
RU570 compared to that against RU570 (3.6-fold increase for
both CCL5 and R4.0) may be due to an altered gp120-CCR5 in-
teraction with an increased reliance on the CCR5 N terminus in
the resistant strain, as this was also previously described for other
R5 viruses that became resistant to small chemical compounds
(31–33). These data confirm that R4.0, like CCL5, may cooperate
with MVC by binding to different CCR5 regions, strengthening
the barrier against HIV-1 infection by lowering the emergence of
virus resistance.
DISCUSSION
The development of new compounds and their combinations to
enhance antiviral efficacy has a timely aspect in HIV-1 research.
CCR5, the major HIV-1 coreceptor, is an important target for the
development of anti-HIV-1 drugs and microbicides, a concept
corroborated by the successful example of MVC, a CCR5-directed
small chemical compound that was approved by the FDA in 2007
for its use in HIV-1-infected people. MVC, a CCR5 antagonist
initially used as a systemic drug, is presently being investigated as
a microbicide to prevent virus transmission during sexual inter-
course. CCR5 is almost exclusively used by HIV-1 isolates in-
volved in primary infection (34), and the presence of CD4 T
lymphocytes and macrophages within the human vaginal epithe-
lium (35, 36) makes an HIV-1 blockade by CCR5 targeting a stra-
tegic option in microbicide development. Ideal CCR5-targeting
anti-HIV-1 compounds should not activate the receptor but
should instead act as CCR5 antagonists to prevent proinflamma-
tory conditions and mucosal inflammation, which may enhance
HIV-1 transmission. CCL5, a natural ligand of CCR5, is a potent
HIV-1 inhibitor (37), and its engineering to enhance anti-HIV-1
activity has been a consistent source of efficient protein-based
inhibitors (11, 38). An important proof of principle for the use of
a CCL5 derivative as a microbicide came from PSC-RANTES.
When applied in a monkey model, PSC-RANTES blocked HIV-1
vaginal transmission (39). However, despite its potent anti-HIV-1
activity, PSC-RANTES is a CCR5 agonist and may elicit inflam-
mation and persistently eliminate CCR5 from the cell surface, its
major mechanism of antiviral action (40). Conversely, a CCR5
antagonist such as R4.0, a CCL5/RANTES-derived peptide with
potent anti-HIV-1 activity (10), should preserve CCR5 cell surface
expression, possibly not altering its physiological function. Full-
length CCL5 derivatives that block HIV-1 as CCR5 antagonists,
such as C1C5-RANTES (41) and the potent compound 5p12-
RANTES (9), are also available. Notably, C1C5-RANTES has been
engineered in recombinant lactobacilli as a potential live microbi-
cide (42), and several novel CCL5 variants have now been pro-
duced by using the same system (M. Secchi and L. Vangelista,
unpublished data), taking advantage of the CCL5 expression pro-
ficiency of lactobacilli (43). Full-length CCL5 and peptide deriva-
tives present similarities (lower HIV-1 resistance) but also mutu-
FIG 4 Combination of CCR5 blockers to inhibit HIV-1BaL infection. (A) HIV-1 inhibition induced by the combination of CCL5 with MVC tested by an
acute-infection assay as described in the legend of Fig. 2. (B) CCL5 combination with MVC tested by a cell fusion inhibition assay using purified human CD4
T cells. (A and B) The dose-response curves of mixed inhibitors (mix) are referred to as CCL5 (P values 0.0001). (C to D) R4.0 in combination with CCL5 (C)
or in triple combination with CCL5 and MVC (D) was tested as described above for panel A. (C and D) The dose-response curves of mixed inhibitors (mix) are
referred to as R4.0 (P values 0.0001). Values are the means	 SD from two independent experiments performed in triplicate.
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ally exclusive advantages and disadvantages, such as antiviral
potency, a molecular size, resistance to proteolysis, and the risk of
eliciting an antibody response.
In this report, we have focused on the investigation of the
CCL5-derived peptide R4.0 through a combination survey with
various classes of HIV-1 inhibitors. The possibility of implement-
ing R4.0-based combinations, with the provision of virus- and
cell-targeting compounds with full additivity or even synergy, has
been proved. The antiviral activity of R4.0-TDF combinations on
two primary R5 HIV-1 strains provided an important in vitro
proof for cross-clade protection. All the HIV-1 inhibitors tested
were suitable for R4.0 combination, and antagonism between the
inhibitors has never been observed, including with a triple com-
bination using IDV and TDF. The compounds tested in combina-
tion with R4.0 recognize HIV-1 gp120 (CV-N and 2G12), gp41
(T20, 2F5, and 4E10), reverse transcriptase (TDF and FTC), pro-
tease (IDV), and human CCR5 (MVC and CCL5). The most in-
teresting information came from the evidence that simultaneous
synergic CCR5 targeting by three different anti-HIV-1 ligands, as
shown here with CCL5, MVC, and R4.0, is possible, a surprising
and inspiring observation. The possibility of targeting CCR5 si-
multaneously with different compounds, such as MVC and CCL5,
has already been reported (27); however, a triple CCR5-targeting
combination further expands the mechanistic view and therapeu-
tic perspective in this direction.
GPCRs may assume several conformations, providing the basis
for allosteric regulation and differential receptor signaling (44).
According to the observed synergic effect of a triple (R4.0-MVC-
CCL5) anti-HIV-1 combination, the experimental evidence sug-
gests that full CCR5 occupancy by these inhibitors occurs in such
a manner that the net result does not comprise antagonism be-
tween the inhibitors. Considering the large surface of interaction
between CCR5 and CCL5 (45), the conformational flexibility of
the receptor, the relatively small targeting site by MVC, and the
occupancy of only a portion of the CCL5 interaction area by R4.0,
a scenario may be conceived in which most CCR5 molecules on
the surface of the target cell are engaged by one or more of these
ligands. A deeper explanation is inspired by a recent report inves-
tigating the CCR5 conformational preferences exerted by natural
CCR5 ligands, 5p12-RANTES, and HIV-1 (46). While the virus
does not discriminate between CCR5 conformations, CCR5-
binding chemokines, including CCL5, have high affinity for nu-
cleotide-free G protein-bound CCR5 and low affinity for CCR5
uncoupled from nucleotide-free G protein (46). Moreover, 5p12-
RANTES seems to contribute its strong antiviral activity via an
enhancement of affinity to nucleotide-free G protein-uncoupled
CCR5, possibly the major CCR5 conformation portal for HIV-1
entry. It is therefore interesting to argue whether R4.0 reached a
similar antiviral improvement through the modification of CCL5
regions other than the chemokine N terminus, i.e., the N-loop/
1-strand. This might be shown by the possibility of testing addi-
FIG 5 R4.0 acts as a CCR5 antagonist. (A to D) Immunofluorescence of CHO
CD4 CCR5 cells labeled with the anti-CCR5 MAb 3A9 (A) or preincubated
with 100 nM CCL5 (B), 100 nM MVC (C), or 100 nM R4.0 (D) and labeled
with 3A9. (E) CHO CD4 CCR5 cell surface CCR5 measured by flow cytometry
was set at 100% for cells treated with 3A9. The CCR5 cell surface expression of
cells preincubated with CCL5, MVC, or R4.0 is shown as a mean percentage of
the expression in control cells	 SD and is representative of two independent
experiments.
FIG 6 The R4.0 and TDF combination inhibits primary R5 HIV-1 strains in acute-infection assays. (A) Inhibition of clade C strain HIV-198IN007; (B) inhibition
of clade B strain HIV-15513. The dose-response curves of mixed inhibitors (mix) are referred to as R4.0 (P values 0.0001). Values are the means	 SD from two
independent experiments performed in triplicate.
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tive/synergic combinations such as R4.0-CCL5 and R4.0-MVC-
CCL5 if we envisage CCL5 occupancy of nucleotide-free G
protein-coupled CCR5 and R4.0 (or MVC-R4.0) occupancy of
nucleotide-free G protein-uncoupled CCR5 totally shutting out
HIV-1 entry. Interestingly, the recently reported three-dimen-
sional structure of a complex between CCR5 and MVC (47) cor-
roborates the hypothesis and experimental evidence discussed
here. Hence, a triple R4.0-MVC-CCL5 combination would likely
result in a complete shielding of the virus docking resources, re-
gardless of a simultaneous triple occupancy per single molecule.
The inhibition of an MVC-resistant virus by CCL5 and R4.0, to-
gether with the difficulty or even inability of R5 HIV-1 strains to
evolve CCL5 resistance (48, 49), most likely mirrored by R4.0,
further validates this type of approach.
In conclusion, our results provide a proof of principle for R4.0
usage in combination with several HIV-1 inhibitors, expand the
view of CCR5 targeting, and corroborate the fight to limit virus
resistance, important conceptual advancements toward the pre-
vention of sexual transmission of HIV-1.
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